Achiko AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHKF research report →
Companywww.achiko.com
Achiko AG engages in developing disruptive diagnostic solutions in Indonesia and internationally. The company's lead product is AptameX, a rapid test that uses DNA aptamers instead of antigens to detect the SARS-CoV-2 virus. It also offers Teman Sehat, a mobile check-in and passport application.
- CEO
- Wern-Yi Goh
- IPO
- 2021
- Employees
- 10
- HQ
- Zurich, CH
Price Chart
Valuation
- Market Cap
- $377.40K
- P/E
- -0.04
- P/S
- 6.04
- P/B
- -0.08
- EV/EBITDA
- -0.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 37.35%
- Op Margin
- -13366.81%
- Net Margin
- -14913.18%
- ROE
- 215.86%
- ROIC
- 471.15%
Growth & Income
- Revenue
- $62.51K · -97.77%
- Net Income
- $-9,321,779 · 33.74%
- EPS
- $-0.07 · 49.79%
- Op Income
- $-8,355,193
- FCF YoY
- -16.97%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.39
- Avg Volume
- 530
Get TickerSpark's AI analysis on ACHKF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ACHKF Coverage
We haven't published any research on ACHKF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACHKF Report →